Email Alert RSS
Volume 13 Issue 5
Sep.  2022
Turn off MathJax
Article Contents
Article Navigation >  Medical Journal of Peking Union Medical College Hospital  > 2022  >  13(5): 789-795
JIN Bao, DU Shunda, MAO Yilei, SANG Xinting. Interpretation on the Updated Points of Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(5): 789-795. doi: 10.12290/xhyxzz.2022-0274
Citation: JIN Bao, DU Shunda, MAO Yilei, SANG Xinting. Interpretation on the Updated Points of Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(5): 789-795. doi: 10.12290/xhyxzz.2022-0274
shu

Interpretation on the Updated Points of Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)

doi: 10.12290/xhyxzz.2022-0274

  • Department of Hepatic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

Funds:

National Natural Science Foundation of China 81972698

More Information
  • Corresponding author: DU Shunda, E-mail: dushd@pumch.cn
  • Received Date: 2022-05-13
  • Accepted Date: 2022-05-27
    • Available Online: 2022-06-22
  • Publish Date: 2022-09-30
    Abstract
  • Since the publication of the Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2019 Edition), many new high-level evidence in line with evidence-based medicine has emerged in the diagnosis and treatment of liver cancer at home and abroad, especially, a number of research results in line with Chinese liver cancer patients have been published. In order to further standardize the diagnosis and treatment of liver cancer in China, the National Health Commission organized multidisciplinary experts in the field of liver cancer to revise and update the Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition), aiming to increase the overall cancer 5-year survival rate by 15%, a goal mentioned in the " Healthy China 2030" Planning Outline. We interpret the main update points of the 2022 version, with the hope of promoting the widespread discussion and dissemination of the new version.
    • FullText(HTML)
  • loading
    • References(39)
  • [1] Zheng RS, Zhang SW, Zeng HM, et al. Cancer incidence and mortality in China, 2016[J]. J Natl Cancer Cent, 2022, 2: 1-9. doi:  10.1016/j.jncc.2022.02.002
    [2] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71: 209-249. doi:  10.3322/caac.21660
    [3] 中华人民共和国卫生部. 原发性肝癌诊疗规范(2011年版)[J]. 临床肿瘤学杂志, 2011, 16: 929-946. doi:  10.3969/j.issn.1009-0460.2011.10.017
    [4] 中华人民共和国卫生和计划生育委员会. 原发性肝癌诊疗规范(2017年版)[J]. 中国实用外科杂志, 2017, 37: 705-720. doi:  10.19538/j.cjps.issn1005-2208.2017.07.01
    [5] 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 中华消化外科杂志, 2020, 19: 1-20. doi:  10.3760/cma.j.issn.1673-9752.2020.01.001
    [6] 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗指南(2022年版)[J]. 中华消化外科杂志, 2022, 21: 143-168. doi:  10.3760/cma.j.cn115610-20220124-00053
    [7] 中共中央国务院. 《"健康中国2030"规划纲要》[EB/OL ]. (2016-10-25)[2022-05-01]. http://www.gov.cn/zhengce/2016-10/25/content_5124174.htm.
    [8] Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables[J]. J Clin Epidemiol, 2011, 64: 383-394. doi:  10.1016/j.jclinepi.2010.04.026
    [9] Balshem H, Helfand M, Schunemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence[J]. J Clin Epidemiol, 2011, 64: 401-406. doi:  10.1016/j.jclinepi.2010.07.015
    [10] Andrews JC, Schunemann HJ, Oxman AD, et al. GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength[J]. J Clin Epidemiol, 2013, 66: 726-735. doi:  10.1016/j.jclinepi.2013.02.003
    [11] Durieux N, Vandenput S, Pasleau F. OCEBM levels of evidence system[J]. Rev Med Liege, 2013, 68: 644-649.
    [12] Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma[J]. J Cancer Res Clin Oncol, 2004, 130: 417-422.
    [13] Fan R, Papatheodoridis G, Sun J, et al. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis[J]. J Hepatol, 2020, 73: 1368-1378. doi:  10.1016/j.jhep.2020.07.025
    [14] Johnson PJ, Pirrie SJ, Cox TF, et al. The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers[J]. Cancer Epidemiol Biomarkers Prev, 2014, 23: 144-153. doi:  10.1158/1055-9965.EPI-13-0870
    [15] Best J, Bechmann LP, Sowa JP, et al. GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis[J]. Clin Gastroenterol Hepatol, 2020, 18: 728-735. e4. doi:  10.1016/j.cgh.2019.11.012
    [16] Caviglia GP, Abate ML, Petrini E, et al. Highly sensitive alpha-fetoprotein, Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxyprothrombin for hepatocellular carcinoma detection[J]. Hepatol Res, 2016, 46: E130-E135. doi:  10.1111/hepr.12544
    [17] Berhane S, Toyoda H, Tada T, et al. Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocel-lular Carcinoma and Prediction of Survival in Patients[J]. Clin Gastroenterol Hepatol, 2016, 14: 875-886. e6. doi:  10.1016/j.cgh.2015.12.042
    [18] Huang C, Fang M, Xiao X, et al. Validation of the GALAD model for early diagnosis and monitoring of hepatocellular carcinoma in Chinese multicenter study[J]. Liver Int, 2022, 42: 210-223. doi:  10.1111/liv.15082
    [19] Wang Y, Tian Y. miRNA for diagnosis and clinical implications of human hepatocellular carcinoma[J]. Hepatol Res, 2016, 46: 89-99. doi:  10.1111/hepr.12571
    [20] Zhou J, Yu L, Gao X, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma[J]. J Clin Oncol, 2011, 29: 4781-4788. doi:  10.1200/JCO.2011.38.2697
    [21] Sheng X, Ji Y, Ren GP, et al. A standardized pathological proposal for evaluating microvascular invasion of hepatocellular carcinoma: a multicenter study by LCPGC[J]. Hepatol Int, 2020, 14: 1034-1047. doi:  10.1007/s12072-020-10111-4
    [22] Zhang X, Li J, Shen F, et al. Significance of presence of microvascular invasion in specimens obtained after surgical treatment of hepatocellular carcinoma[J]. J Gastroenterol Hepatol, 2018, 33: 347-354. doi:  10.1111/jgh.13843
    [23] Park JW, Chen M, Colombo M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study[J]. Liver Int, 2015, 35: 2155-2166. doi:  10.1111/liv.12818
    [24] 中国抗癌协会肝癌专业委员会转化治疗协作组. 肝癌转化治疗中国专家共识(2021版)[J]. 中华消化外科杂志, 2021, 20: 600-616. doi:  10.3760/cma.j.cn115610-20210512-00223
    [25] Kaseb AO, Hasanov E, Cao HST, et al. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial[J]. Lancet Gastroenterol Hepatol, 2022, 7: 208-218. doi:  10.1016/S2468-1253(21)00427-1
    [26] Shi HY, Wang SN, Wang SC, et al. Preoperative transarterial chemoembolization and resection for hepatocellular carcinoma: a nationwide Taiwan database analysis of long-term outcome predictors[J]. J Surg Oncol, 2014, 109: 487-493. doi:  10.1002/jso.23521
    [27] Zhou WP, Lai EC, Li AJ, et al. A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma[J]. Ann Surg, 2009, 249: 195-202. doi:  10.1097/SLA.0b013e3181961c16
    [28] Singal AG, Lim JK, Kanwal F. AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review[J]. Gastroenterology, 2019, 156: 2149-2157. doi:  10.1053/j.gastro.2019.02.046
    [29] Sapena V, Enea M, Torres F, et al. Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis[J]. Gut, 2022, 71: 593-604. doi:  10.1136/gutjnl-2020-323663
    [30] Kulik L, Heimbach JK, Zaiem F, et al. Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta-analysis[J]. Hepatology, 2018, 67: 381-400. doi:  10.1002/hep.29485
    [31] Lee S, Kim KW, Song GW, et al. The Real Impact of Bridging or Downstaging on Survival Outcomes after Liver Transplantation for Hepatocellular Carcinoma[J]. Liver Cancer, 2020, 9: 721-733. doi:  10.1159/000507887
    [32] Mazzaferro V, Citterio D, Bhoori S, et al. Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial[J]. Lancet Oncol, 2020, 21: 947-956. doi:  10.1016/S1470-2045(20)30224-2
    [33] Mehta N, Guy J, Frenette CT, et al. Excellent Outcomes of Liver Transplantation Following Down-Staging of Hepatocellular Carcinoma to Within Milan Criteria: A Multicenter Study[J]. Clin Gastroenterol Hepatol, 2018, 16: 955-964. doi:  10.1016/j.cgh.2017.11.037
    [34] Nordness MF, Hamel S, Godfrey CM, et al. Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are checkpoint inhibitors safe for the pretransplant patient?[J]. Am J Transplant, 2020, 20: 879-883. doi:  10.1111/ajt.15617
    [35] Gao Q, Anwar IJ, Abraham N, et al. Liver Transplantation for Hepatocellular Carcinoma after Downstaging or Bridging Therapy with Immune Checkpoint Inhibitors[J]. Cancers (Basel), 2021, 13: 6307. doi:  10.3390/cancers13246307
    [36] Qu S, Worlikar T, Felsted AE, et al. Non-thermal histotripsy tumor ablation promotes abscopal immune responses that enhance cancer immunotherapy[J]. J Immunother Cancer, 2020, 8: e000200. doi:  10.1136/jitc-2019-000200
    [37] Greten TF, Mauda-Havakuk M, Heinrich B, et al. Combined locoregional-immunotherapy for liver cancer[J]. J Hepatol, 2019, 70: 999-1007. doi:  10.1016/j.jhep.2019.01.027
    [38] Mizukoshi E, Yamashita T, Arai K, et al. Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma[J]. Hepatology, 2013, 57: 1448-1457. doi:  10.1002/hep.26153
    [39] Slovak R, Ludwig JM, Gettinger SN, et al. Immuno-thermal ablations-boosting the anticancer immune response[J]. J Immunother Cancer, 2017, 5: 78. doi:  10.1186/s40425-017-0284-8
    • Relative Articles(0)
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (3769) PDF downloads(457) Cited by()
    Proportional views
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return